SavedAdd your journal

Journals / Journal of Clinical and Analytical Medicine / 2015 / Cilt: 6 - Sayı: 1

Hipertansiyonda Endotelin Seviyeleri, Ekokardiyografi Bulguları ve Valsartan Tedavisiyle İlişkisi

The Relationship in Hypertensive Patients Endothelin Levels, Echocardiographic Findings and Valsartan

Kenan SAGLAM
Coşkun MERİC
Hüseyin CAKİROGLU
Muhammed ERDAL
Pages
46–49
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Compatible to previous studies, serum ET evels of the hypertensive patients were higher than ofthe healthy controls (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: It is estimated that treatment options which lower endothelin (ET) levels may be a new treatment approach for hypertensive patients.
📊
Key Findings & Data:Material and Method: Twenty-three patients (14 men,9 women) with an age range of 33-70 years having Stage 1 (n=3) or StageII (n=20) hypertension according to the criteria defined by the Joint NationalCommittee Report VII (JNC VII) were included.
💡
Conclusion & Impact:Results: Compatible to previous studies, serum ET evels of the hypertensive patients were higher than ofthe healthy controls (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: It is estimated that treatment options which lower endothelin (ET) levels may be a new treatment approach for hypertensive patients. For thispurpose in this study, we investigated whether the antihypertensive effect ofvalsartan is due to its effect on serum ET levels or not. In addition to this, therelationship between serum ET evels and left ventricular hypertrophy (LVH)was also determined. Material and Method: Twenty-three patients (14 men,9 women) with an age range of 33-70 years having Stage 1 (n=3) or StageII (n=20) hypertension according to the criteria defined by the Joint NationalCommittee Report VII (JNC VII) were included. Results: Compatible to previous studies, serum ET evels of the hypertensive patients were higher than ofthe healthy controls (p

Özet

Amaç: Endotelin düzeylerini azaltan tedavi seçeneklerinin, hipertansiyon tedavisinde yeni bir yaklaşım olabileceği düşünülmüştür. Bu nedenle bu araştırmada Valsartan%u2019nın hipertansiyon tedavisindeki iyileştirici etkilerinin, endotelin düzeylerine de olan etkisinden kaynaklanıp kaynaklanmadığı araştırılmıştır. Aynı zamanda endotelin düzeyleri ile sol ventrikül hipertrofisi arasındaki ilişki değerlendirilmiştir. Gereç ve Yöntem: Çalışmaya toplam 14%u2019ü erkek, 9%u2019u kadın olmak üzere, 33-70 yaş aralığında, JNC VII ölçütlerine göre; evre I (n:3) ve evre II (n:20) birincil yüksek kan basınçlı 23 hasta dahil edilmiştir. Bulgular: Sağlıklı bireylerde leptin ve endotelin düzeyleri, literatürle uyumlu olarak hipertansiflere göre düşük bulunmuştur (p

🔖

Cite This Article

SAGLAM, K., MERİC, C., CAKİROGLU, H., ERDAL, M. (2022). Hipertansiyonda Endotelin Seviyeleri, Ekokardiyografi Bulguları ve Valsartan Tedavisiyle İlişkisi. Journal of Clinical and Analytical Medicine, Cilt: 6 - Sayı: 1, 46–49. https://ajindex.com/articles/560948

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Barry JM, Richard AP. Angiotensin-converting enzyme ınhibitors in hypertension. Arch Intern Med 1994;154(5):513-23
  2. Kayaalp O, editors. Tıbbi farmakoloji. İstanbul: 2000.p.445-6
  3. Schunkert H, Jahn L, Izumo S, Apstein CS, Lorell BH. Localization and regulation of c-fos and c-jun prooncogene ınduction by sistolic wall stres in normal and hypertrophied rat heart. Proc Natl Acad Sci USA 1991;88(24):11480-4
  4. Kaplan NM. Systemic hypertension mechanisms and diagnosis. In: Braunwald E,editors. A text-book of Cardiovascular Medicine. 4nd ed. Philadelphia, London, Toronto: Ran Press; 1992.p.817-46
  5. Levy D, Savage DD, Garrison RJ, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322(22):1561-6
  6. Messerli FH, Soria F. Hypertension, left ventricular ectopy and sudden death. Am J Med 1992;93(Suppl 2A):215-6
  7. Verdecchia P, Schillaci G, Guerri M. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990;81(2):528-36
  8. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; DOI: 10.1161/01.CIR.102.19.2434
  9. Torun E, Bayram F. Endothelium as an endocrine organ and role of endothelin in hypertension. Erciyes Med J 2004;26(3):126-31
  10. Pollock DM. Endothelin, angiotensin and oxidative stress in hypertension. Hypertension 2005; DOI:10.1161/01.HYP.0000158262.11935
  11. Letizia C, Cerci S, De Toma G, Ambrosiyo CD, De Ciocchis A, Coassin S, et al. High plasma endothelin-1 levels in hypertensive patients with low-renin essential hypertension. J Human Hypert 1997;11(7):447–51
  12. Vanhoutte PM. Is endothelin involved in the pathogenesis of hypertension? Hypertension 1993;21(6):747-51
  13. Ernesto LS. Vascular endothelin in hypertension. Vasc Pharmacol 2005; DOI: 10.1016/j.vph.2005.03.004
  14. Da Silva AA, Kuo JJ, Tallam LS, Hall JE. Role of endothelin-1 in blood pres- sure regulation in a rat model of visceral obesity and hypertension. Hypertension 2004;43(2):383-7
  15. Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18(5):797-810
  16. Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z. Cardiovascular hypertrophy in diabetic spontaneously hyperten